Our Services

Molecular diagnostics

Our Molecular Oncology Laboratory integrates advanced molecular diagnostics with clinical and translational expertise to deliver actionable insights for precision oncology. Our multidisciplinary team of molecular scientists and pathologists operates in an ISO 15189-accredited environment, using state-of-the-art technologies to support diagnosis, treatment decisions and clinical trial enrollment.

We specialize in comprehensive genomic and transcriptomic profiling across tissue and liquid biopsy, enabling the detection of clinically relevant alterations that drive tumor progression and therapeutic response.

CORE CAPABILITIES:

KEY TECHNOLOGIES & PLATFORMS:

Comprehensive Genomic Profiling – TSO500 v2 (NEW):

PANGAEA has recently incorporated the TSO500 v2 (Illumina) platform, marking a major milestone in our molecular diagnostics capabilities and reinforcing our position at the forefront of precision oncology.

This advanced next-generation sequencing (NGS) solution enables comprehensive genomic profiling in a single assay, providing deep molecular insights to guide clinical decision-making and accelerate drug development.

Why TSO500 v2 matters

  • Simultaneous detection of:

    • Single nucleotide variants (SNVs)

    • Insertions and deletions (indels)

    • Copy number variations (CNVs)

    • Gene fusions (RNA)

  • Analysis of 500+ cancer-related genes

  • Integrated biomarkers:

    • Tumor Mutational Burden (TMB)

    • Microsatellite Instability (MSI)

One test. Hundreds of genes. Infinite possibilities in precision oncology.

RAPID MOLECULAR TESTING – IDYLLA PLATFORM

We have incorporated the IDYLLA platform to provide fast and reliable molecular diagnostics with minimal hands-on time.

Our portfolio includes a rapid POLE mutation detection test, enabling the identification of POLE/POLD1 alterations in just a few days, supporting clinical decision-making in tumors such as endometrial and colorectal cancer.

liquid biopsy

We offer highly sensitive liquid biopsy solutions based on blood-derived samples, enabling:

  • Non-invasive tumor profiling

  • Real-time monitoring of treatment response

  • Early detection of resistance mechanisms

This approach overcomes limitations associated with tissue availability and enables longitudinal patient monitoring in precision oncology

PANGAEA is one of the leading European providers in liquid biopsy and the first pharmacogenomics laboratory in Spain accredited by ENAC (ISO 15189, nº 750/LE1556) for genetic testing in liquid biopsy samples.

Regulatory compliance (IVDR Art. 5.5) Pangaea Oncology publishes its public declaration on the use of laboratory-developed tests. View declaration.

Our experience is endorsed by the numerous clinical trials in which we were selected as a reference laboratory.

Want to better understand your tumor and explore personalized treatment options?

Our team is here to help